Title:
抗がん融合タンパク質
Document Type and Number:
Japanese Patent JP5759557
Kind Code:
B2
Abstract:
A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Inventors:
Piechikoran, Jelci Szczepan
Remke, Kurtistov Kajima Miju
Paulauk, Sebastian Dominique
Zelek, Bartowomiille Mathieu
Remke, Kurtistov Kajima Miju
Paulauk, Sebastian Dominique
Zelek, Bartowomiille Mathieu
Application Number:
JP2013541381A
Publication Date:
August 05, 2015
Filing Date:
December 05, 2011
Export Citation:
Assignee:
ADAMED SP.Z O.O.
International Classes:
C07K19/00; A61K38/00; A61P35/00; C07K14/525; C07K14/56; C07K14/57; C12N1/21; C12N15/09
Domestic Patent References:
| JP2004503512A | ||||
| JP2010532978A |
Other References:
Shin et al.,Experimental cell research,Vol.312,p.3892-3898(2006)
Gerspach et al.,Cancer Immunology Immunotherapy,Vol.55,p.1590-1600(2006)
Clark et al.,Journal of Urology,Vol,184, No.3,p.1166-1174(2010.09)
Gerspach et al.,Cancer Immunology Immunotherapy,Vol.55,p.1590-1600(2006)
Clark et al.,Journal of Urology,Vol,184, No.3,p.1166-1174(2010.09)
Attorney, Agent or Firm:
Kiyoji Kuzuwa